News
-
-
PRESS RELEASE
ProteinQure to Present Data on PQ203, a Novel Peptide-Drug Conjugate for Triple Negative Breast Cancer, at 2024 San Antonio Breast Cancer Symposium
ProteinQure to present promising data on PQ203, a peptide drug conjugate for TNBC treatment, at 2024 San Antonio Breast Cancer Symposium. Phase 1 trial in 2025 -
-
PRESS RELEASE
ProteinQure Announces A Breakthrough Therapeutic with Remarkable Efficacy in Heterogenous Patient-Derived Xenograft Models of Triple-Negative Breast Cancer to be presented at AACR
ProteinQure announces breakthrough in triple-negative breast cancer treatment through novel Peptide Drug Conjugate with exceptional efficacy in lab experiments -